1. Home
  2. STXS vs PBYI Comparison

STXS vs PBYI Comparison

Compare STXS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STXS
  • PBYI
  • Stock Information
  • Founded
  • STXS 1990
  • PBYI 2010
  • Country
  • STXS United States
  • PBYI United States
  • Employees
  • STXS N/A
  • PBYI N/A
  • Industry
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • STXS Health Care
  • PBYI Health Care
  • Exchange
  • STXS Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • STXS 254.1M
  • PBYI 237.2M
  • IPO Year
  • STXS 2004
  • PBYI N/A
  • Fundamental
  • Price
  • STXS $3.09
  • PBYI $5.15
  • Analyst Decision
  • STXS
  • PBYI Strong Buy
  • Analyst Count
  • STXS 0
  • PBYI 1
  • Target Price
  • STXS N/A
  • PBYI $7.00
  • AVG Volume (30 Days)
  • STXS 539.3K
  • PBYI 505.1K
  • Earning Date
  • STXS 11-10-2025
  • PBYI 11-06-2025
  • Dividend Yield
  • STXS N/A
  • PBYI N/A
  • EPS Growth
  • STXS N/A
  • PBYI 434.29
  • EPS
  • STXS N/A
  • PBYI 0.97
  • Revenue
  • STXS $31,806,000.00
  • PBYI $238,062,000.00
  • Revenue This Year
  • STXS $30.98
  • PBYI N/A
  • Revenue Next Year
  • STXS $49.86
  • PBYI N/A
  • P/E Ratio
  • STXS N/A
  • PBYI $5.31
  • Revenue Growth
  • STXS 33.94
  • PBYI 8.63
  • 52 Week Low
  • STXS $1.54
  • PBYI $2.32
  • 52 Week High
  • STXS $3.59
  • PBYI $6.07
  • Technical
  • Relative Strength Index (RSI)
  • STXS 52.79
  • PBYI 61.06
  • Support Level
  • STXS $3.16
  • PBYI $4.37
  • Resistance Level
  • STXS $3.59
  • PBYI $4.79
  • Average True Range (ATR)
  • STXS 0.18
  • PBYI 0.23
  • MACD
  • STXS 0.02
  • PBYI 0.05
  • Stochastic Oscillator
  • STXS 33.78
  • PBYI 74.89

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: